|
Class 2 Device Recall STA Neooplastine CI 10 |
|
Date Initiated by Firm |
October 20, 2008 |
Date Posted |
December 18, 2008 |
Recall Status1 |
Terminated 3 on June 24, 2010 |
Recall Number |
Z-0501-2009 |
Recall Event ID |
50125 |
Product Classification |
Prothrombin Time Test - Product Code GJS
|
Product |
STA Neoplastine CI 10; Product Catalogue Number: 0666; Manufactured by Diagnostica Stago, Asnieres, France. |
Code Information |
Lot 101393, 101465, 101676, and 102269. |
Recalling Firm/ Manufacturer |
Diagnostica Stago, Inc. 5 Century Dr Parsippany NJ 07054-4607
|
For Additional Information Contact |
Umberto V. Parrotta 973-631-1200 Ext. 2044
|
Manufacturer Reason for Recall |
Internal investigation has determined the potential lack of homogeneity between product vials.
|
FDA Determined Cause 2 |
Process control |
Action |
Product Recall Notice letters were sent to all customers on October 20, 2008 vis US mail. The letter stated the reason for the notice, the corrective action, and replacement process. Customers are to confirm that they received the Recall Notice by completing the attached "Product Recall Response Form" and return by fax to the Regulatory Affairs Department at 973-867-6028 or 973-695-0095. The firm is prepared to immediately implement the following corrective action: 1) perform QC testing in accordance to directions from the package insert on each vial and destroy vial and replace inventory if determined product was unsatisfactory OR 2) return inventory for replacement with new lots of inventory. If customers have any questions or need any technical assistance, they are to call the DSI Hotline at 1-800-222-2624, option 1. |
Quantity in Commerce |
1,280 units |
Distribution |
Nationwide Distribution. |
Total Product Life Cycle |
TPLC Device Report
|
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
|
|
|
|